[123I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease.
Identifieur interne : 003881 ( PubMed/Checkpoint ); précédent : 003880; suivant : 003882[123I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease.
Auteurs : Willibald Gerschlager [Autriche] ; Gerhard Bencsits ; Walter Pirker ; Bastiaan R. Bloem ; Susanne Asenbaum ; Daniella Prayer ; Jan C M. Zijlmans ; Martha Hoffmann ; Thomas BrückeSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2002.
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Cocaine (analogs & derivatives), Cocaine (diagnostic use), Corpus Striatum (metabolism), Corpus Striatum (radionuclide imaging), Diagnosis, Differential, Dopamine (metabolism), Female, Humans, Male, Middle Aged, Nerve Degeneration (metabolism), Nerve Degeneration (radionuclide imaging), Parkinson Disease (metabolism), Parkinson Disease (radionuclide imaging), Parkinson Disease, Secondary (metabolism), Parkinson Disease, Secondary (radionuclide imaging), Radiopharmaceuticals (diagnostic use), Tomography, Emission-Computed, Single-Photon.
- MESH :
- chemical , analogs & derivatives : Cocaine.
- chemical , diagnostic use : Cocaine, Radiopharmaceuticals.
- metabolism : Corpus Striatum, Dopamine, Nerve Degeneration, Parkinson Disease, Parkinson Disease, Secondary.
- radionuclide imaging : Corpus Striatum, Nerve Degeneration, Parkinson Disease, Parkinson Disease, Secondary.
- Aged, Aged, 80 and over, Diagnosis, Differential, Female, Humans, Male, Middle Aged, Tomography, Emission-Computed, Single-Photon.
Abstract
We investigated whether [(123)I]-beta-CIT and single-photon emission computed tomography (SPECT) imaging distinguishes patients with clinically suspected vascular parkinsonism (VP) from patients with idiopathic Parkinson's disease (PD). [(123)I]beta-CIT SPECT is a sensitive marker of dopaminergic degeneration, and the degree of striatal binding reduction in PD correlates with disease severity. Thirteen patients who fulfilled rigid clinical criteria for VP (mean +/- S.D.: age, 76.5 +/- 5.3 years; disease duration, 3.6 +/- 2.8 years), 20 PD patients (age, 66.2 +/- 9.5 years; disease duration, 4.3 +/- 2.7 years), and 30 healthy persons (age, 44.6 +/- 19.2 years) underwent [(123)I]beta-CIT SPECT imaging. Age-corrected striatal beta-CIT binding was reduced on average by 40.8% in PD but was near normal in the VP group (mean reduction, 1.2%). This difference was statistically significant (Z = 4.68; P < 0.001). The left-right asymmetry of striatal beta-CIT binding was significantly increased in the PD group compared with normal controls and the VP group (F(2) = 17.4, P <0.001). Moreover, putamen-caudate nucleus ratios were significantly reduced in PD compared with both VP patients and healthy controls (F(2) = 65.5, P < 0.001). Whole striatal beta-CIT binding was more than one standard deviation above the mean PD values in all but one of the individual VP patients. Our findings suggest that the presynaptic dopaminergic deficits seen in PD are absent in most patients with VP. [(123)I]beta-CIT SPECT imaging may be useful to help distinguish between PD and VP patients during life.
DOI: 10.1002/mds.10092
PubMed: 12112200
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:12112200Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[123I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease.</title><author><name sortKey="Gerschlager, Willibald" sort="Gerschlager, Willibald" uniqKey="Gerschlager W" first="Willibald" last="Gerschlager">Willibald Gerschlager</name><affiliation wicri:level="3"><nlm:affiliation>Department of Clinical Neurology, University of Vienna, Vienna, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Clinical Neurology, University of Vienna, Vienna</wicri:regionArea><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation></author><author><name sortKey="Bencsits, Gerhard" sort="Bencsits, Gerhard" uniqKey="Bencsits G" first="Gerhard" last="Bencsits">Gerhard Bencsits</name></author><author><name sortKey="Pirker, Walter" sort="Pirker, Walter" uniqKey="Pirker W" first="Walter" last="Pirker">Walter Pirker</name></author><author><name sortKey="Bloem, Bastiaan R" sort="Bloem, Bastiaan R" uniqKey="Bloem B" first="Bastiaan R" last="Bloem">Bastiaan R. Bloem</name></author><author><name sortKey="Asenbaum, Susanne" sort="Asenbaum, Susanne" uniqKey="Asenbaum S" first="Susanne" last="Asenbaum">Susanne Asenbaum</name></author><author><name sortKey="Prayer, Daniella" sort="Prayer, Daniella" uniqKey="Prayer D" first="Daniella" last="Prayer">Daniella Prayer</name></author><author><name sortKey="Zijlmans, Jan C M" sort="Zijlmans, Jan C M" uniqKey="Zijlmans J" first="Jan C M" last="Zijlmans">Jan C M. Zijlmans</name></author><author><name sortKey="Hoffmann, Martha" sort="Hoffmann, Martha" uniqKey="Hoffmann M" first="Martha" last="Hoffmann">Martha Hoffmann</name></author><author><name sortKey="Brucke, Thomas" sort="Brucke, Thomas" uniqKey="Brucke T" first="Thomas" last="Brücke">Thomas Brücke</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2002">2002</date><idno type="RBID">pubmed:12112200</idno><idno type="pmid">12112200</idno><idno type="doi">10.1002/mds.10092</idno><idno type="wicri:Area/PubMed/Corpus">003A58</idno><idno type="wicri:Area/PubMed/Curation">003A58</idno><idno type="wicri:Area/PubMed/Checkpoint">003881</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[123I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease.</title><author><name sortKey="Gerschlager, Willibald" sort="Gerschlager, Willibald" uniqKey="Gerschlager W" first="Willibald" last="Gerschlager">Willibald Gerschlager</name><affiliation wicri:level="3"><nlm:affiliation>Department of Clinical Neurology, University of Vienna, Vienna, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Clinical Neurology, University of Vienna, Vienna</wicri:regionArea><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation></author><author><name sortKey="Bencsits, Gerhard" sort="Bencsits, Gerhard" uniqKey="Bencsits G" first="Gerhard" last="Bencsits">Gerhard Bencsits</name></author><author><name sortKey="Pirker, Walter" sort="Pirker, Walter" uniqKey="Pirker W" first="Walter" last="Pirker">Walter Pirker</name></author><author><name sortKey="Bloem, Bastiaan R" sort="Bloem, Bastiaan R" uniqKey="Bloem B" first="Bastiaan R" last="Bloem">Bastiaan R. Bloem</name></author><author><name sortKey="Asenbaum, Susanne" sort="Asenbaum, Susanne" uniqKey="Asenbaum S" first="Susanne" last="Asenbaum">Susanne Asenbaum</name></author><author><name sortKey="Prayer, Daniella" sort="Prayer, Daniella" uniqKey="Prayer D" first="Daniella" last="Prayer">Daniella Prayer</name></author><author><name sortKey="Zijlmans, Jan C M" sort="Zijlmans, Jan C M" uniqKey="Zijlmans J" first="Jan C M" last="Zijlmans">Jan C M. Zijlmans</name></author><author><name sortKey="Hoffmann, Martha" sort="Hoffmann, Martha" uniqKey="Hoffmann M" first="Martha" last="Hoffmann">Martha Hoffmann</name></author><author><name sortKey="Brucke, Thomas" sort="Brucke, Thomas" uniqKey="Brucke T" first="Thomas" last="Brücke">Thomas Brücke</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2002" type="published">2002</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Cocaine (analogs & derivatives)</term><term>Cocaine (diagnostic use)</term><term>Corpus Striatum (metabolism)</term><term>Corpus Striatum (radionuclide imaging)</term><term>Diagnosis, Differential</term><term>Dopamine (metabolism)</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Nerve Degeneration (metabolism)</term><term>Nerve Degeneration (radionuclide imaging)</term><term>Parkinson Disease (metabolism)</term><term>Parkinson Disease (radionuclide imaging)</term><term>Parkinson Disease, Secondary (metabolism)</term><term>Parkinson Disease, Secondary (radionuclide imaging)</term><term>Radiopharmaceuticals (diagnostic use)</term><term>Tomography, Emission-Computed, Single-Photon</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Cocaine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Cocaine</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Corpus Striatum</term><term>Dopamine</term><term>Nerve Degeneration</term><term>Parkinson Disease</term><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Corpus Striatum</term><term>Nerve Degeneration</term><term>Parkinson Disease</term><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Diagnosis, Differential</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Tomography, Emission-Computed, Single-Photon</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We investigated whether [(123)I]-beta-CIT and single-photon emission computed tomography (SPECT) imaging distinguishes patients with clinically suspected vascular parkinsonism (VP) from patients with idiopathic Parkinson's disease (PD). [(123)I]beta-CIT SPECT is a sensitive marker of dopaminergic degeneration, and the degree of striatal binding reduction in PD correlates with disease severity. Thirteen patients who fulfilled rigid clinical criteria for VP (mean +/- S.D.: age, 76.5 +/- 5.3 years; disease duration, 3.6 +/- 2.8 years), 20 PD patients (age, 66.2 +/- 9.5 years; disease duration, 4.3 +/- 2.7 years), and 30 healthy persons (age, 44.6 +/- 19.2 years) underwent [(123)I]beta-CIT SPECT imaging. Age-corrected striatal beta-CIT binding was reduced on average by 40.8% in PD but was near normal in the VP group (mean reduction, 1.2%). This difference was statistically significant (Z = 4.68; P < 0.001). The left-right asymmetry of striatal beta-CIT binding was significantly increased in the PD group compared with normal controls and the VP group (F(2) = 17.4, P <0.001). Moreover, putamen-caudate nucleus ratios were significantly reduced in PD compared with both VP patients and healthy controls (F(2) = 65.5, P < 0.001). Whole striatal beta-CIT binding was more than one standard deviation above the mean PD values in all but one of the individual VP patients. Our findings suggest that the presynaptic dopaminergic deficits seen in PD are absent in most patients with VP. [(123)I]beta-CIT SPECT imaging may be useful to help distinguish between PD and VP patients during life.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">12112200</PMID><DateCreated><Year>2002</Year><Month>07</Month><Day>11</Day></DateCreated><DateCompleted><Year>2002</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>3</Issue><PubDate><Year>2002</Year><Month>May</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>[123I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>518-23</MedlinePgn></Pagination><Abstract><AbstractText>We investigated whether [(123)I]-beta-CIT and single-photon emission computed tomography (SPECT) imaging distinguishes patients with clinically suspected vascular parkinsonism (VP) from patients with idiopathic Parkinson's disease (PD). [(123)I]beta-CIT SPECT is a sensitive marker of dopaminergic degeneration, and the degree of striatal binding reduction in PD correlates with disease severity. Thirteen patients who fulfilled rigid clinical criteria for VP (mean +/- S.D.: age, 76.5 +/- 5.3 years; disease duration, 3.6 +/- 2.8 years), 20 PD patients (age, 66.2 +/- 9.5 years; disease duration, 4.3 +/- 2.7 years), and 30 healthy persons (age, 44.6 +/- 19.2 years) underwent [(123)I]beta-CIT SPECT imaging. Age-corrected striatal beta-CIT binding was reduced on average by 40.8% in PD but was near normal in the VP group (mean reduction, 1.2%). This difference was statistically significant (Z = 4.68; P < 0.001). The left-right asymmetry of striatal beta-CIT binding was significantly increased in the PD group compared with normal controls and the VP group (F(2) = 17.4, P <0.001). Moreover, putamen-caudate nucleus ratios were significantly reduced in PD compared with both VP patients and healthy controls (F(2) = 65.5, P < 0.001). Whole striatal beta-CIT binding was more than one standard deviation above the mean PD values in all but one of the individual VP patients. Our findings suggest that the presynaptic dopaminergic deficits seen in PD are absent in most patients with VP. [(123)I]beta-CIT SPECT imaging may be useful to help distinguish between PD and VP patients during life.</AbstractText><CopyrightInformation>Copyright 2002 Movement Disorder Society</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gerschlager</LastName><ForeName>Willibald</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurology, University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bencsits</LastName><ForeName>Gerhard</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Pirker</LastName><ForeName>Walter</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Bloem</LastName><ForeName>Bastiaan R</ForeName><Initials>BR</Initials></Author><Author ValidYN="Y"><LastName>Asenbaum</LastName><ForeName>Susanne</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Prayer</LastName><ForeName>Daniella</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Zijlmans</LastName><ForeName>Jan C M</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Hoffmann</LastName><ForeName>Martha</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Brücke</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>133647-95-7</RegistryNumber><NameOfSubstance UI="C069723">RTI 55</NameOfSubstance></Chemical><Chemical><RegistryNumber>I5Y540LHVR</RegistryNumber><NameOfSubstance UI="D003042">Cocaine</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003042">Cocaine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000031">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000176">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003342">Corpus Striatum</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003937">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004298">Dopamine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009410">Nerve Degeneration</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010302">Parkinson Disease, Secondary</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="N" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019275">Radiopharmaceuticals</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000176">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015899">Tomography, Emission-Computed, Single-Photon</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>7</Month><Day>12</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>9</Month><Day>17</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>7</Month><Day>12</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12112200</ArticleId><ArticleId IdType="doi">10.1002/mds.10092</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Autriche</li></country><region><li>Vienne (Autriche)</li></region><settlement><li>Vienne (Autriche)</li></settlement></list><tree><noCountry><name sortKey="Asenbaum, Susanne" sort="Asenbaum, Susanne" uniqKey="Asenbaum S" first="Susanne" last="Asenbaum">Susanne Asenbaum</name><name sortKey="Bencsits, Gerhard" sort="Bencsits, Gerhard" uniqKey="Bencsits G" first="Gerhard" last="Bencsits">Gerhard Bencsits</name><name sortKey="Bloem, Bastiaan R" sort="Bloem, Bastiaan R" uniqKey="Bloem B" first="Bastiaan R" last="Bloem">Bastiaan R. Bloem</name><name sortKey="Brucke, Thomas" sort="Brucke, Thomas" uniqKey="Brucke T" first="Thomas" last="Brücke">Thomas Brücke</name><name sortKey="Hoffmann, Martha" sort="Hoffmann, Martha" uniqKey="Hoffmann M" first="Martha" last="Hoffmann">Martha Hoffmann</name><name sortKey="Pirker, Walter" sort="Pirker, Walter" uniqKey="Pirker W" first="Walter" last="Pirker">Walter Pirker</name><name sortKey="Prayer, Daniella" sort="Prayer, Daniella" uniqKey="Prayer D" first="Daniella" last="Prayer">Daniella Prayer</name><name sortKey="Zijlmans, Jan C M" sort="Zijlmans, Jan C M" uniqKey="Zijlmans J" first="Jan C M" last="Zijlmans">Jan C M. Zijlmans</name></noCountry><country name="Autriche"><region name="Vienne (Autriche)"><name sortKey="Gerschlager, Willibald" sort="Gerschlager, Willibald" uniqKey="Gerschlager W" first="Willibald" last="Gerschlager">Willibald Gerschlager</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003881 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 003881 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:12112200
|texte= [123I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:12112200" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |